Vanda Pharmaceuticals Gain Following FDA Approval of Bipolar, Schizophrenia Treatment
By Connor Hart
Shares of Vanda Pharmaceuticals climbed after the company received approval from the Food and Drug Administration for its treatment of a type of bipolar disorder, as well as schizophrenia.
The stock rose 39% to $7.90 in premarket trading Monday. Through Friday's close, shares are up more than 32% over the past year.
The biopharmaceutical company said late Friday that the treatment, called Bysanti, was approved in adults for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of schizophrenia.
Vanda said Bysanti is expected to be commercially available in the third quarter. The company added that marketing exclusivity for the drug will be protected by regulatory data exclusivity and issued U.S. patents, with the latest expiring in 2044.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
February 23, 2026 07:01 ET (12:01 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States